Abstract
Migraine is a common disorder that generates direct and indirect costs to health systems. In the pathiphysiology of migraine there are involved genetic, environmental, neurophysiological, and biochemical factors.
Triptans are 5HT-1 receptor agonists and they constitute the most important abortive therapy for migraine, their main mechanisms of action are: vasoconstriction, peripheral neuronal inhibition, and inhibition of the transmission of impulses through the second order neurons in the trigeminocervical complex.
This review provides a comparison between the clinical effectiveness of the different triptans and discusses their pharmacological characteristics, adverse effects, security, the costs of the treatment and their impact on the labor productivity.
References
- Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003; 9: 45-52.
- Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptán on work productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Man Care 1996; 1407-1416.
- Badia X, Magaz S, Gutierrez L, Galvan J. The burden of migraine in Spain: Beyond direct costs. Pharmacoeconomics 2004; 22: 591-603.
- Becker WJ. Are the triptans for migraine therapy worth the cost? Can J Neurol 2000; 27: 111-115.
- Belsey JD. Cost effectiveness of oral triptan therapy: A transnational comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004; 20: 659-669
- Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of Migraine. Curr Neurology and Neuroscience Reports 2004; 4: 98-104.
- Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55: 27-36.
- Burstein R, Jakubowski M. Implications of multimechanism therapy: when to treat? Neurology 2005; 64 (Suppl 2): S16-S20.
- Caro JJ, Caro G, Getsios D, Raggio G, Burrows M, Black
L. The migraine ACE model: Evaluating the impact on time lost and medical resource use. Headache 2000; 40: 282-291.
- Christoph-Diener H, Ferrari M, Mansbach H, SNAP database study group. Predicting the response to sumatriptán. The sumatriptán naratriptán aggregate patient database. Neurology 2004; 63: 520-524.
- Connor HE, Beattie DT. Naratriptán-therapy. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 124-133.
- Connor HE. Sumatriptán-pharmacology. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 83-92.
- Cumberbatch MJ, Hill RG, Hargreaves RJ. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by 5HT1B-5HT1D agonist. Br J Pharmacol 1999; 126: 1478-1486.
- Dahlöf C, Lines C. Rizatriptán-therapy. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 162-172.
- Diener H. Sumatriptán-therapy. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger 2000; 17: 93-109.
- Diener HC. Eletriptán-therapy. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger 2000; 17: 184- 189.
- Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5HT1B/1D agonists) in the acute treatment of migraine. Headache 2004; 44: 414-425.
- Edmeads J. Zolmitriptán-therapy. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 116-123.
- Ferrari M D, Roon KI, Lipton RB, Goadsby PJ. Oral triptan (serotonin 5HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-1675.
- Ferrari M. Which oral triptan to choose ? In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 216-221.
- Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538-545.
- Géraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological and pharmacokinetic properties of triptans. Headache 2003; 43: 376-388.
- Géraud G,. The acute treatment of migraine with frovatriptán. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 206-215.
- Goadsby P. Treatment of acute migraine attacks with naratriptán. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 134-140.
- Goadsby PJ. The pharmacology of migraine. Prog Neurobiol 2000; 62: 509-525.
- Gracia-Naya M. Coste-eficacia del tratamiento con triptanes en España. Rev Neurol 2001; 921-924.
- Gupta P, McHarg A, Morgan P. A profile of the preclinical pharmacology and pharmacokinetics of eletriptán. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 173-183.
- Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine. The risk of stroke, cardiovascular disease and death in practice. Neurology 2004; 62: 563-568.
- Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptán. Headache 2002; 42: 984-999.
- Hargreaves RJ, Longmore J, Beer M, et al. The pharmacology and mechanisms of action of rizatriptán. In Diener HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 141-161.
- Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5HT receptors. Pharmacol Biochem Behav 2002; 71: 533-554.
- John GW, Goadsby PJ. Triptan signal transduction. In Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA. eds: The Headaches.3rd Ed. Philadelphia, PA USA. Lippincott Williams and Wilkins; 2006: 203-211.
- Jones MB, Siderovski DP, Hooks SB. The G ß? dimer as a novel source of selectivity in G-protein signaling: GCL-ing at convention. Mol Interv 2004; 4: 200-214.
- Levy D, Jakuboswski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5-HT1B/1D receptor agonist. USA Proc Natl Acad Sci 2004; 101: 4272-4279.
- Limmroth V, Katsarava Z, Liedert B et al. An in vivo rat model to study calcitonin gen related peptide release following activation of the trigeminal vascular system. Pain 2001; 92: 101-106.
- Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine study II. Headache 2001; 41: 638-645.
- Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment ? Headache 2002; 42 (Suppl 1): S3-S9.
- Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38: 87-96.
- Lofland JH, Kim SS, batenhorst AS et al. Cost-effectiveness and cost-benefit of sumatriptán in patients with migraine. Mayo Clin Proc 2001; 76: 1093-1101.
- Lyngberg A, Jensen R, Rasmussen BK, Jorgensen T. Incidence of migraine in a Danish population-based follow-up study. Cephalalgia 2003; 23: 596. (Abstract)
- Marentette MA, Desjardins B, Gerth WC. The productivity cost benefit of maxalt 10 mg vs usual migraine therapy in Canada. Headache 2000; 40: 419.
- Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 2004; 63: 848-852.
- Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Headache 1996; 35: 488-489.
- Mii S, Khalil RA, Morgan KG et al. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol 1996; 270: H142-50.
- Morillo LE, Sanin LC, Alarcón F, et al. Epidemiology of migraine in Latin American urban communities: Prevalence, clinical characteristics and medication use. Headache 2004; 44:
- Olesen J, Goadsby PJ. Synthesis of migraine mechanisms. In Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds: The Headaches. 3rd Ed. Philadelphia, PA USA. Lippincott Williams and Wilkins, 2006: 393-398.
- Papademetriou V. Cardiovascular risk assessment and triptans. Headache 2004; 44 (Suppl 1): S31-S39.
- Pascual J. Clinical Benefits of Early Triptan Therapy for Migraine. Headache 2002; 42 (Suppl 1): 10-17.
- Pascual J. Therapy with other triptans: Almotriptán. In Diener, ed HC: Drug Treatment of migraine and other headaches. Monogr Clin Neurosci. Basel, Karger. 2000; 17: 197-205.
- Putnam GP, O’quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and tolerability of sumatriptán: a large-scale, prospective study. Cephalalgia 1999; 19: 668-675.
- Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations. How to match patients and products. CNS 2003; 17: 431-447.
- Robbins L. Frequent triptan use: Observations on safety issues. Headache 2004; 44: 178-182.
- Roncolato M, Arpinelli F, Fabbri L, et al. The cost of the migraine patient in Italy. J Headache Pain 2000; 1: 173-177.
- Saxena PR, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonist in the acute treatment of migraines. In Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA. eds: The Headaches. 3rd Ed. Philadelphia, PA USA. Lippincott Williams and Wilkins. 2006: 469-503.
- Schoenen J. When should triptans be taken during a migraine attack ? CNS Drugs 2001; 15: 583-587.
- Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptán in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000; 75: 782-789.
- Sheffield RE. Migraine prevalence: A literature review. Headache 1998; 38: 595-601.
- Shepheard SL, Williamson DJ, Beer MS et al. Differential effects of 5HT 1B/1D receptor agonist on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 1997; 36: 525-533.
- Tepper S, Allen C, sanders D, Greene A, Boccuzzi S. Co-prescription of triptans with potentially interacting medications: a cohort study involving 240.268 patients. Headache 2003; 43: 44-48.
- Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003; 2: 123-132.
- Tfelt-Hansen P, DeVries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259-1287.
- Volcy M. El Impacto Social, Económico y en Sistema de Salud secundario a Migraña y otras Cefaleas Primarias. Rev Neurol 2006 (En impresión).
- Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000; 18: 557-566. Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptán and sumatriptán in the treatmet of acute migraine using a composite efficacy/tolerability end point. J Manag care Pharm 2004; 10: 259-269.
- Zgombick JM, Borden LA, Cochran TL, et al. Dual coupling of cloned human 5-hydroxytryptamine1Dalpha and 5-hydroxytryptamine1Dbeta receptors stably expressed in murine fibroblast: Inhibition of adenylate cyclase and elevation of intracellular calcium concentration via pertussis toxin-sensitive G protein(s). Mol Pharmacol 1993; 44: 575-582.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.